Table 1. . Basic characteristics of eligible studies (n = 9).

Study, year	Origin	Design	Condition	Comparison	Sample size	Male patients	Age, years	Patients with grade A/B (n)	Patients with grade C/D (n)	Treatment period
Ashida, et al., 2015	Japan	Multi-center	EE	VPZ5	148	110	57.9 ± 12.9	88	55	8 weeks
				VPZ10	145	113	57.3 ± 13.0	89	44
				VPZ20	154	115	58.3 ± 13.8	94	50
				VPZ40	146	114	57.6 ± 12.8	84	51
				LPZ30	140	99	55.8 ± 13.9	86	47
Ashida, et al., 2016	Japan	Multi-center	EE	VPZ20	207	137	58.3 ± 13.8	132	75	8 weeks
				LPZ30	202	154	57.4 ± 13.2	129	73
Chen, et al., 2018	China	Multi-center	EE	VPZ20	142	105	51.8 ± 13.7	89	54	8 weeks
				LPZ30	133	110	51.5 ± 12.5	85	46
Xiao, et al., 2020	China	Multi-center	EE	VPZ20	244	176	54.1 ± 13.2	168	76	8 weeks
				LPZ30	237	179	53.8 ± 12.5	167	68
Okanobu, et al., 2021	Japan	Single-center	EE	VPZ10	36	24	62 (38–83)	29	7	4 weeks
				VPZ20	37	26	69 (35–85)	28	9
Iwakiri, et al., 2017	Japan	Multi-center	Refractory EE	VPZ20	9	5	73.8 ± 7.5	2	3	8 weeks
				VPZ40	10	3	71.2 ± 10.5	6	2
Huang, et al., 2021	China	Single-center	Refractory EE	VPZ20	30	14	44.3 ± 16.4	10	20	4 weeks
				EPZ20	30	17	45.5 ± 17.3	12	18
Uemura, et al., 2019	Japan	Multi-center	EE	VPZ20	139	n.a.	n.a.	n.a.	n.a.	8 weeks
				LPZ30	69	n.a.	n.a.	n.a.	n.a.
Sakurai, et al., 2019	Japan	Multi-center	EE	VPZ20	22	6	58.0 ± 13.8	10	3	4 weeks
				EPZ20	25	10	54.7 ± 13.2	9	3

EE: Erosive esophagitis; EPZ: Esomeprazole; LPZ: Lansoprazole; n.a.: Not applicable; VPZ: Vonoprazan.